Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Change in Receivables (2019 - 2025)

Karyopharm Therapeutics' Change in Receivables history spans 7 years, with the latest figure at -$5.7 million for Q4 2025.

  • For Q4 2025, Change in Receivables fell 463.14% year-over-year to -$5.7 million; the TTM value through Dec 2025 reached -$4.6 million, down 220.61%, while the annual FY2025 figure was -$4.6 million, 220.61% down from the prior year.
  • Change in Receivables reached -$5.7 million in Q4 2025 per KPTI's latest filing, down from -$1.1 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $6.9 million in Q2 2024 to a low of -$11.9 million in Q1 2023.
  • Average Change in Receivables over 5 years is -$310400.0, with a median of $89500.0 recorded in 2021.
  • Peak YoY movement for Change in Receivables: soared 358.61% in 2022, then crashed 8219.26% in 2023.
  • A 5-year view of Change in Receivables shows it stood at $3.7 million in 2021, then plummeted by 96.4% to $135000.0 in 2022, then plummeted by 8219.26% to -$11.0 million in 2023, then soared by 90.77% to -$1.0 million in 2024, then plummeted by 463.14% to -$5.7 million in 2025.
  • Per Business Quant, the three most recent readings for KPTI's Change in Receivables are -$5.7 million (Q4 2025), -$1.1 million (Q3 2025), and -$2.3 million (Q2 2025).